Lupin Limited announced on June 16 that it has entered into a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of Tiotropium Dry Powder Inhaler (18 mcg/capsule) in China. This inhaler is used in the treatment of chronic obstructive pulmonary disease (COPD).
As per the deal, Sino Universal will handle regulatory approvals and distribution in China, while Lupin will retain marketing authorization and manage manufacturing. This marks a strategic push for Lupin to expand its respiratory product portfolio in one of the world’s fastest-growing pharmaceutical markets.
Fabrice Egros, President of Corporate Development at Lupin, said the partnership underscores Lupin’s commitment to global respiratory care. Wang Li, President of SUP, praised the collaboration, emphasizing how it aligns with SUP’s mission to bring international innovation to China.
This development is expected to enhance Lupin’s global respiratory footprint, especially in a country witnessing a rising burden of COPD.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
